AR124480A1 - Métodos de purificación de proteínas de fusión con protección de carga - Google Patents

Métodos de purificación de proteínas de fusión con protección de carga

Info

Publication number
AR124480A1
AR124480A1 ARP210103633A ARP210103633A AR124480A1 AR 124480 A1 AR124480 A1 AR 124480A1 AR P210103633 A ARP210103633 A AR P210103633A AR P210103633 A ARP210103633 A AR P210103633A AR 124480 A1 AR124480 A1 AR 124480A1
Authority
AR
Argentina
Prior art keywords
protected
fusion protein
cargo
biologically active
cell lysate
Prior art date
Application number
ARP210103633A
Other languages
English (en)
Inventor
Christopher Kable Means
Shahparak Zaltash
Nina Mp Stelzer
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Pfenex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd, Pfenex Inc filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of AR124480A1 publication Critical patent/AR124480A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/424—Elution mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates

Abstract

La presente invención se refiere a un método para purificar las proteínas con protección de carga a partir del lisado celular o liberado periplásmico usando cromatografía de interacción hidrofóbica como una primera etapa de cromatografía. Asimismo, en la presente, también se proveen las composiciones que comprenden proteínas con protección de carga y los métodos de tratamiento utilizando proteínas purificadas con protección de carga. Reivindicación 1: En algunas formas de realización, en la presente se proporciona un método para purificar una proteína de fusión con protección de carga a partir de un lisado celular o un liberado periplásmico, en donde la proteína de fusión con protección de carga comprende un dominio biológicamente activo y un dominio con protección de carga, y en donde el método comprende una cromatografía de interacción hidrofóbica como una primera etapa de la cromatografía. Reivindicación 2: En algunas formas de realización, en la presente se proporciona un método para producir una proteína de fusión con protección de carga a partir de un lisado celular o un liberado periplásmico, en donde la proteína de fusión con protección de carga comprende un dominio biológicamente activo y un dominio con protección de carga, en donde el método comprende i) cultivar células que comprenden un ácido nucleico que codifica la proteína de fusión con protección de carga; y ii) purificar la proteína de fusión con protección de carga, en donde la proteína con protección de carga se purifica a partir del lisado celular o liberado periplásmico usando cromatografía de interacción hidrofóbica como primera etapa de cromatografía. Reivindicación 17: Un método para producir una proteína de fusión PASilada biológicamente activa a partir de un lisado celular o un liberado periplásmico que comprende i) cultivar células que comprenden un ácido nucleico que codifica la proteína de fusión PASilada biológicamente activa; y ii) purificar la proteína de fusión PASilada biológicamente activa, y en donde la proteína PASilada biológicamente activa se purifica a partir del lisado celular o liberado periplásmico usando cromatografía de interacción hidrofóbica como primera etapa de cromatografía. Reivindicación 18: Un método para purificar una proteína de fusión con protección de carga que comprende un dominio biológicamente activo y un dominio de protección de carga de un lisado celular o liberación periplásmica, el método comprende las siguientes etapas en orden i) aplicar una solución de carga que comprende la proteína de fusión con protección de carga a una columna de cromatografía de interacción hidrofóbica; ii) aplicar una solución de lavado a la columna de cromatografía de interacción hidrofóbica; iii) aplicar una solución de elución a la columna de interacción hidrofóbica para eluir la proteína con protección de carga; vi) aplicar la proteína de fusión con protección de carga eluida en iii) como una solución de carga a una columna de cromatografía de intercambio aniónico; v) eluir la proteína de fusión con protección de carga de la columna de cromatografía de intercambio aniónico; vi) aplicar la proteína de fusión con protección de carga eluida en vi) como una solución de carga a una columna de cromatografía de intercambio catiónico; vii) aplicar una solución de lavado a la columna de cromatografía de intercambio viii) aplicar una solución de elución a la columna de cromatografía de intercambio de cationes para eluir la proteína con protección de carga.
ARP210103633A 2020-12-23 2021-12-22 Métodos de purificación de proteínas de fusión con protección de carga AR124480A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063130295P 2020-12-23 2020-12-23

Publications (1)

Publication Number Publication Date
AR124480A1 true AR124480A1 (es) 2023-03-29

Family

ID=80118858

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210103633A AR124480A1 (es) 2020-12-23 2021-12-22 Métodos de purificación de proteínas de fusión con protección de carga

Country Status (11)

Country Link
US (1) US20220227805A1 (es)
EP (1) EP4267592A1 (es)
JP (1) JP2024500974A (es)
KR (1) KR20230125179A (es)
CN (1) CN116916966A (es)
AR (1) AR124480A1 (es)
AU (1) AU2021410080A1 (es)
CA (1) CA3179177A1 (es)
IL (1) IL303948A (es)
TW (1) TW202241922A (es)
WO (1) WO2022140783A1 (es)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
US4755465A (en) 1983-04-25 1988-07-05 Genentech, Inc. Secretion of correctly processed human growth hormone in E. coli and Pseudomonas
US5281532A (en) 1983-07-27 1994-01-25 Mycogen Corporation Pseudomas hosts transformed with bacillus endotoxin genes
US4695455A (en) 1985-01-22 1987-09-22 Mycogen Corporation Cellular encapsulation of pesticides produced by expression of heterologous genes
US4695462A (en) 1985-06-28 1987-09-22 Mycogen Corporation Cellular encapsulation of biological pesticides
US5128130A (en) 1988-01-22 1992-07-07 Mycogen Corporation Hybrid Bacillus thuringiensis gene, plasmid and transformed Pseudomonas fluorescens
US5055294A (en) 1988-03-03 1991-10-08 Mycogen Corporation Chimeric bacillus thuringiensis crystal protein gene comprising hd-73 and berliner 1715 toxin genes, transformed and expressed in pseudomonas fluorescens
US5169760A (en) 1989-07-27 1992-12-08 Mycogen Corporation Method, vectors, and host cells for the control of expression of heterologous genes from lac operated promoters
US6406632B1 (en) 1998-04-03 2002-06-18 Symyx Technologies, Inc. Rapid characterization of polymers
US7294513B2 (en) 2002-07-24 2007-11-13 Wyatt Technology Corporation Method and apparatus for characterizing solutions of small particles
US9453251B2 (en) 2002-10-08 2016-09-27 Pfenex Inc. Expression of mammalian proteins in Pseudomonas fluorescens
AU2007275535B2 (en) 2006-06-30 2012-08-16 Servier IP UK Limited Recombinant host for producing L-asparaginase II
CA2663047A1 (en) 2006-09-06 2008-03-13 Phase Bioscience, Inc. Therapeutic elastin-like polypeptide (elp) fusion proteins
EP2054521A4 (en) * 2006-10-03 2012-12-19 Novo Nordisk As METHODS OF PURIFYING CONJUGATES OF POLYPEPTIDES
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
WO2013130684A1 (en) * 2012-02-27 2013-09-06 Amunix Operating Inc. Xten-folate conjugate compositions and methods of making same
EP4180525A1 (en) * 2017-06-21 2023-05-17 Jazz Pharmaceuticals Ireland Limited Modified l-asparaginase
EP3418383A1 (en) * 2017-06-21 2018-12-26 XL-protein GmbH Modified l-asparaginase
CN111278852A (zh) 2017-10-27 2020-06-12 菲尼克斯公司 重组欧氏杆菌天冬酰胺酶的生产方法

Also Published As

Publication number Publication date
IL303948A (en) 2023-08-01
CA3179177A1 (en) 2022-06-30
TW202241922A (zh) 2022-11-01
US20220227805A1 (en) 2022-07-21
EP4267592A1 (en) 2023-11-01
JP2024500974A (ja) 2024-01-10
AU2021410080A1 (en) 2023-06-22
KR20230125179A (ko) 2023-08-29
WO2022140783A1 (en) 2022-06-30
CN116916966A (zh) 2023-10-20

Similar Documents

Publication Publication Date Title
Bower et al. The N-DRC forms a conserved biochemical complex that maintains outer doublet alignment and limits microtubule sliding in motile axonemes
Heinemeyer et al. Proteomic approach to characterize the supramolecular organization of photosystems in higher plants
US20160024141A1 (en) Ion exchange purification of mrna
O'Donnell et al. Total reconstitution of DNA polymerase III holoenzyme reveals dual accessory protein clamps.
RU2007132851A (ru) Способ мягкой распределительной хроматографии
CL2018000537A1 (es) Anticuerpo anti-factor d del complemento; polinucleótido codificante; vector que comprende dicho polinucleótido; célula húesped que comprende dicho vector; método de fabricación de anticuerpo; composición farmacéutica que lo comprende; uso del anticuerpo para tratar trastornos inflamatorios o trastornos oculares (divisional de cl 1001-2009).
US20200017545A1 (en) Methods and Reagents for Purification of Proteins
PT100988A (pt) Processo para a purificacao de anticorpos
AR080200A1 (es) Genes delta-endotoxinicos axmi221z, axmi222z, axmi223z, axmi224z, y axmi225z y metodos para su uso
AR074015A1 (es) Purificacion de proteinas acidas utilizando cromatografia de hidroxiapatita ceramica
JPS62501414A (ja) ヒルジン様蛋白質をコードするｄｎａ
CA2058676C (en) Process for isolating human albumin from supernatant iv, in particular iv-4, or from cohn's fraction v or from an analogous supernatant or fraction
JP2020000259A5 (es)
BR112017019401A2 (pt) método de purificação de proteínas de fusão de albumina
Kreimendahl et al. The selectivity filter of the mitochondrial protein import machinery
AR124480A1 (es) Métodos de purificación de proteínas de fusión con protección de carga
Ashcheulova et al. Production of the recombinant antimicrobial peptide UBI18-35 in Escherichia coli
HRP20171736T1 (hr) Postupak proizvodnje i pročišćavanja rekombinantne lizosomske alfa-manozidaze
KR20180116159A (ko) 양이온 교환 크로마토그래피를 이용한 유사항체 정제 방법
Taylor et al. Natively oxidized amino acid residues in the spinach cytochrome b 6 f complex
KR101414897B1 (ko) 다베포에틴 알파의 정제 방법
ATE522617T1 (de) Verfahren zur aufreinigung von interferon-beta
JP6303379B2 (ja) 抗体の精製方法
Rahman et al. Emerging promise of therapeutic approaches targeting mitochondria in neurodegenerative disorders
Timasheff et al. Studies on acid deoxyribonuclease: VII. Conformation of three nucleases in solution